Natural protein points to new inflammation treatment

NIH | APRIL 2, 2016

Increasing the level of a naturally-produced protein, called tristetraprolin (TTP), significantly reduced or protected mice from inflammation, according to researchers.

Structure of the ZFP36 protein (TTP). Image credit: Emw/Wikipedia (CC BY-SA 3.0)

The results suggest that pharmaceutical compounds or other therapeutic methods that produce elevated levels of TTP in humans may offer an effective treatment for some inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.

Inflammation has been proven to play a major role in a number of normal processes in humans, but it also fosters diseases, many of which are increasing in prevalence and severity. The development of new therapies for treating inflammatory diseases could greatly reduce the growing health burden.

A team from National Institute of Environmental Health Sciences genetically altered the TTP gene in mice, so that the animals produced higher than normal amounts of the TTP protein. The mice were then tested using experimental models of rheumatoid arthritis, psoriasis, and multiple sclerosis. Experimental models are used to study processes thought to be involved in human diseases, and to evaluate and select therapies that affect these processes.

Mice with more TTP in their bodies were resistant to the inflammation that accompanied these experimental models of disease.

The TTP exerts its beneficial effect by targeting several messenger molecules that encode cytokines, proteins known to be involved in inflammation. TTP binds to these molecules and destabilizes them, resulting in lower levels of cytokines and, thus, decreased inflammation.

The TTP-based treatments would be cost effective and easy to administer. Future work will seek to identify compounds that have similar effects on the levels of TTP in the body.

YOU MAY ALSO LIKE

Researchers rescue photoreceptors, prevent blindness in animal models of retinal degeneration

Using a novel patient-specific stem cell-based therapy, researchers at the National Eye Institute prevented blindness in animal models of geographic atrophy, the advanced "dry" form of age-related macular degeneration.

New stem cell combination could help to repair damaged hearts

A combination of heart cells derived from human stem cells could be the answer to developing a desperately-needed treatment for heart failure, according to new research by scientists at the University of Cambridge.

Trigger for Milky Way’s Youngest Supernova Identified

Astronomers had previously identified G1.9+0.3 as the remnant of the most recent supernova in our Galaxy. It is estimated to have occurred about 110 years ago in a dusty region of the Galaxy that blocked visible light from reaching Earth.

In blinding eye disease, trash-collecting cells go awry, accelerate damage

Spider-like cells inside the brain, spinal cord and eye hunt for invaders, capturing and then devouring them. These cells, called microglia, often play a beneficial role by helping to clear trash and protect the central nervous system against infection. But a new study shows that they also accelerate damage wrought by blinding eye disorders, such as retinitis pigmentosa.

Molecule created in Brazil helps fight heart failure

A molecule designed at the Institute of Biomedical Sciences of the University of São Paulo (ICB-USB) may increase the quality of life and life expectancy of people suffering from congestive heart failure.

Eyes of CJD patients show evidence of prions

Scientists have found evidence of the infectious agent of sporadic Creutzfeldt-Jakob disease (CJD) in the eyes of deceased CJD patients. The finding suggests that the eye may be a source for early CJD diagnosis and raises questions about the safety of routine eye exams and corneal transplants.